---
figid: PMC8984255__po-6-e2100370-g002
figtitle: PIK3CA Mutations Drive Therapeutic Resistance in Human Epidermal Growth
  Factor Receptor 2–Positive Breast Cancer
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC8984255
filename: po-6-e2100370-g002.jpg
figlink: /pmc/articles/PMC8984255/figure/fig1/
number: F1
caption: 'The PI3K pathway: normal and cancerous conditions and targeted agents. (A)
  Under normal conditions, the PI3K pathway contributes to the regulation of cell
  growth, proliferation, and survival via receptor tyrosine kinases including HER2
  leading to downstream activation of AKT and mTOR complexes. (B) Inappropriate/excessive
  activation of the pathway caused by HER2 amplification, PIK3CA alteration, and/or
  PTEN loss-of-function can contribute to the formation of breast cancer via dysregulated
  cell growth, proliferation, and survival. (C) Pharmacologic agents targeting the
  PI3K pathway include PI3K, mTOR, and dual PI3/mTOR inhibitors. HER2, human epidermal
  growth factor receptor 2; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol
  3-kinase; PIP2, phosphatidylinositol diphosphate; PIP3, phosphatidylinositol 3-phosphate;
  PTEN, phosphatase and tensin homolog.'
papertitle: PIK3CA Mutations Drive Therapeutic Resistance in Human Epidermal Growth
  Factor Receptor 2–Positive Breast Cancer.
reftext: Aryana R. Rasti, et al. JCO Precis Oncol. 2022;6:e2100370.
year: '2022'
doi: 10.1200/PO.21.00370
journal_title: JCO Precision Oncology
journal_nlm_ta: JCO Precis Oncol
publisher_name: Wolters Kluwer Health
keywords: ''
automl_pathway: 0.7948756
figid_alias: PMC8984255__F1
figtype: Figure
redirect_from: /figures/PMC8984255__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8984255__po-6-e2100370-g002.html
  '@type': Dataset
  description: 'The PI3K pathway: normal and cancerous conditions and targeted agents.
    (A) Under normal conditions, the PI3K pathway contributes to the regulation of
    cell growth, proliferation, and survival via receptor tyrosine kinases including
    HER2 leading to downstream activation of AKT and mTOR complexes. (B) Inappropriate/excessive
    activation of the pathway caused by HER2 amplification, PIK3CA alteration, and/or
    PTEN loss-of-function can contribute to the formation of breast cancer via dysregulated
    cell growth, proliferation, and survival. (C) Pharmacologic agents targeting the
    PI3K pathway include PI3K, mTOR, and dual PI3/mTOR inhibitors. HER2, human epidermal
    growth factor receptor 2; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol
    3-kinase; PIP2, phosphatidylinositol diphosphate; PIP3, phosphatidylinositol 3-phosphate;
    PTEN, phosphatase and tensin homolog.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - l(1)G0020
  - Taf4
  - Rpn2
  - Sap-r
  - pan
  - Panx
  - Crtc
  - Pten
  - Mtor
  - Tor
  - amon
  - Pdk1
  - Akt
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - CUX1
  - SART3
  - ERBB2
  - ADA2
  - MTOR
  - RPTOR
  - PTEN
  - PDK1
  - PDPK1
  - AKT1
  - AKT2
  - AKT3
  - MAPKAP1
  - RICTOR
  - MLST8
---
